ChemiCare | It's a rare thing to care
Cutting-edge drugs for calcium-related diseases
4 employees · est. 2016 · Novara, Italy
Entrada Therapeutics
Innovating to transform the treatment of serious diseases through establishing a new class of genetic medicines.
207 employees · est. 2016 · Boston, United States
Entrada Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | ChemiCare | It's a rare thing to care | Entrada Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2016 | 2016 |
| Headquarters | ||
| Headquarters | Novara, Italy | Boston, United States |
| Employees | ||
| Employees | 4 | 207 larger |
| Industry | ||
| Industry | Health Care, Pharmaceutical | Biotechnology |
| Funding Stage | ||
| Funding Stage | Grant | IPO |
| Total Funding | ||
| Total Funding | $71.43K | $483.10M |
| Funding Rounds | ||
| Funding Rounds | 1 | 7 |
| Services | ||
| Services | Not tracked yet | Development of intracellular therapeutics, Clinical trials, Research on undruggable targets, Development of disease-specific therapies |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with neuromuscular disorders, Families affected by Duchenne Muscular Dystrophy, Researchers and medical professionals, Biotechnology investors |
| Taxonomy | ||
| Taxonomy | Orphan Drugs, Genetic Diseases, Calcium-related Diseases, Duchenne Muscular Dystrophy, Tubular Aggregate Myopathies, Autoimmune Disorders, Intracellular Calcium Level, Rare Diseases, Drug Discovery, Therapy Development | Intracellular Therapeutics, Genetic Medicines, Neuromuscular Diseases, Inherited Retinal Diseases, Oligonucleotide Programs, Duchenne Muscular Dystrophy, Exon Skipping, Myotonic Dystrophy Type 1, Clinical-stage Biopharmaceutical, Boston Seaport Community, Proprietary Approaches, Versatile And Modular Development, Biopharma Innovation, Disease Transformation |
| Website | ||
| Website | chemicare.it | entradatx.com |
About ChemiCare | It's a rare thing to care
ChemiCare is an innovative SME founded in December 2016, with a commitment to the discovery and development of orphan drugs for patients affected by calcium-related genetic diseases. The company's mission is to improve the quality of life for patients suffering from rare diseases such as Duchenne Mu...
About Entrada Therapeutics
Entrada Therapeutics, founded in 2016, is a clinical-stage biopharmaceutical company based in Boston’s Seaport community. The company is committed to transforming therapeutic approaches for challenging diseases by focusing on intracellular targets previously deemed unreachable. With a mission encaps...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at ChemiCare | It's a rare thing to care and Entrada Therapeutics — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at ChemiCare | It's a rar... and Entrada Therapeutics — by email.
Frequently Asked Questions
Compare ChemiCare | It's a rare thing to care with someone else
Start typing a company name or domain.